ARCH THERAPEUTICS, INC.: 10-Q filed 2022-08-11
What ARCH THERAPEUTICS, INC. reported in its quarterly report filed 2022-08-11 (fiscal Q3 2022): 31 published measures, 83 facts as tagged in accession 0001851734-22-000438.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-08-11
- Fiscal period
- fiscal Q3 2022
- Accession
- 0001851734-22-000438 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARCH THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 1,573,091 | USD | |
| At 2021-09-30 | 3,676,485 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 5,588,590 | USD | |
| At 2021-09-30 | 4,702,159 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | -4,015,499 | USD | |
| At 2022-03-31 | -3,059,424 | USD | |
| At 2021-09-30 | -1,025,674 | USD | |
| At 2021-06-30 | 615,633 | USD | |
| At 2021-03-31 | 2,051,682 | USD | |
| At 2020-09-30 | -1,500,491 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -1,046,830 | USD | 91 |
| 2021-10-01 to 2022-06-30 | -3,387,295 | USD | 273 |
| 2021-04-01 to 2021-06-30 | -1,529,905 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -4,475,305 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | -2,786,642 | USD | 273 |
| 2020-10-01 to 2021-06-30 | -4,446,077 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 0 | USD | 273 |
| 2020-10-01 to 2021-06-30 | 3,275 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 575,000 | USD | 273 |
| 2020-10-01 to 2021-06-30 | 7,269,233 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 0 | USD | 273 |
| 2020-10-01 to 2021-06-30 | -3,275 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | -53,184,214 | USD | |
| At 2021-09-30 | -49,796,919 | USD |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 0 | USD/shares | 91 |
| 2021-10-01 to 2022-06-30 | -0.01 | USD/shares | 273 |
| 2021-04-01 to 2021-06-30 | -0.01 | USD/shares | 91 |
| 2020-10-01 to 2021-06-30 | -0.02 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 2,843 | USD | |
| At 2021-09-30 | 5,240 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 397,470 | USD | 273 |
| 2020-10-01 to 2021-06-30 | 372,196 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -1,006,940 | USD | 91 |
| 2021-10-01 to 2022-06-30 | -4,267,624 | USD | 273 |
| 2021-04-01 to 2021-06-30 | -1,667,948 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -4,652,276 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 1,566,748 | USD | |
| At 2021-09-30 | 3,667,745 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 39,890 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 119,671 | USD | 273 |
| 2021-04-01 to 2021-06-30 | 40,186 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 110,202 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 1,919,307 | USD | |
| At 2021-09-30 | 1,727,547 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 1,696,213 | USD | |
| At 2021-09-30 | 408,083 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 1,428,264 | USD | |
| At 2021-09-30 | 1,093,765 | USD |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 17,140 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 51,363 | USD | 273 |
| 2021-04-01 to 2021-06-30 | 0 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 10,102 | USD | 273 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 836,215 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 3,308,227 | USD | 273 |
| 2021-04-01 to 2021-06-30 | 1,370,395 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 3,600,419 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 159,846 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 922,120 | USD | 273 |
| 2021-04-01 to 2021-06-30 | 297,553 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 1,051,755 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 236,994,770 | shares | |
| At 2021-09-30 | 236,719,770 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 48,931,720 | USD | |
| At 2021-09-30 | 48,534,525 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 33,756 | USD | |
| At 2021-09-30 | 33,756 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 30,913 | USD | |
| At 2021-09-30 | 28,516 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 3,500 | USD | |
| At 2021-09-30 | 3,500 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 83,487 | USD | |
| At 2021-09-30 | 307,341 | USD |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 799 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 2,397 | USD | 273 |
| 2020-10-01 to 2021-06-30 | 1,788 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -39,890 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 880,329 | USD | 273 |
| 2021-04-01 to 2021-06-30 | 138,043 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 176,971 | USD | 273 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 582,572 | USD | 273 |
| 2020-10-01 to 2021-06-30 | 42,215 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 1,288,130 | USD | 273 |
| 2020-10-01 to 2021-06-30 | -64,853 | USD | 273 |
Inspect the source
- Entity
- ARCH THERAPEUTICS, INC. / CIK 0001537561
- Captured
- SEC response SHA-256
63d0e84748ee59ab7c6817be68d0a32b23d83273213bc50081bb86253a1d4cc2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001537561.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))